About: Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus
Creator	Boukhvalova, M Falsey, A Mond, J Blanco, Jcg
Source	Medline; PMC
abstract	Respiratory syncytial virus (RSV) is a significant cause of bronchiolitis and pneumonia in several high health risk populations, including infants, elderly and immunocompromised individuals. Mortality in hematopoietic stem cell transplant recipients with lower respiratory tract RSV infection can exceed 80%. It has been shown that RSV replication in immunosuppressed individuals is significantly prolonged, but the contribution of pulmonary damage, if any, to the pathogenesis of RSV disease in this susceptible population is not known. In this work, we tested RI-002, a novel standardized Ig formulation containing a high level of RSV-neutralizing Ab, for its ability to control RSV infection in immunocompromised cotton rats Sigmodon hispidus. Animals immunosuppressed by repeat cyclophosphamide injections were infected with RSV and treated with RI-002. Prolonged RSV replication, characteristic of immunosuppressed cotton rats, was inhibited by RI-002 administration. Ab treatment reduced detection of systemic dissemination of viral RNA. Importantly, pulmonary interstitial inflammation and epithelial hyperplasia that were significantly elevated in immunosuppressed animals were reduced by RI-002 administration. These results indicate the potential of RI-002 to improve outcome of RSV infection in immunocompromised subjects not only by controlling viral replication, but also by reducing damage to lung parenchyma and epithelial airway lining, but further studies are needed.
has issue date	2015-09-14(xsd:dateTime)
bibo:doi	10.1038/bmt.2015.212
bibo:pmid	26367224
has license	no-cc
sha1sum (hex)	31664c61ab1f092fcf9a5a7bc0cf3a9534819ca9
schema:url	https://doi.org/10.1038/bmt.2015.212
resource representing a document's title	Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus
has PubMed Central identifier	PMC7091900
has PubMed identifier	26367224
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:31664c61ab1f092fcf9a5a7bc0cf3a9534819ca9#body_text
is schema:about of	named entity 'DAMAGE' named entity 'IMMUNOCOMPROMISED' named entity 'RSV' named entity 'pneumonia' named entity 'damage' named entity 'improve' named entity 'treated' named entity 'exceed' named entity 'RSV' named entity 'immunocompromised' named entity 'CONTROLS' named entity 'VIRAL REPLICATION' named entity 'VIRAL RNA' named entity 'SIGMODON HISPIDUS' named entity 'BUT' named entity 'DISSEMINATION' named entity 'STUDIES' named entity 'NOT KNOWN' named entity 'INJECTIONS' named entity 'RSV INFECTION' named entity 'EPITHELIAL' named entity 'REPEAT' named entity 'AIRWAY' named entity 'LUNG PARENCHYMA' named entity 'HEALTH RISK' named entity 'NOVEL' named entity 'SUBJECTS' named entity 'PULMONARY' named entity 'COTTON RATS' named entity 'SUSCEPTIBLE POPULATION' named entity 'IS A' named entity 'PATHOGENESIS' named entity 'INTERSTITIAL INFLAMMATION' named entity 'RSV' named entity 'INCLUDING' named entity 'CONTAINING' named entity 'PNEUMONIA' named entity 'HIGH' named entity 'DETECTION' named entity 'CYCLOPHOSPHAMIDE' named entity 'POTENTIAL' named entity 'VIRAL REPLICATION' named entity 'RSV' named entity 'PULMONARY' named entity 'CONTROLLING' named entity 'NEEDED' named entity 'REDUCING' named entity 'SIGNIFICANT' named entity 'NOVEL' named entity 'TREATED WITH' named entity 'ANIMALS' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'TREATMENT' named entity 'MORTALITY' named entity 'EPITHELIAL HYPERPLASIA' named entity 'SIGMODON HISPIDUS' named entity 'TESTED' named entity 'CAUSE' named entity 'RISK POPULATIONS' named entity 'DISEASE' named entity 'RESULTS' named entity 'PROLONGED' named entity 'TREATMENT' named entity 'INDIVIDUALS' named entity 'ELDERLY' named entity 'FORMULATION' named entity 'REDUCED' named entity 'THESE' named entity 'ADMINISTRATION' named entity 'TRANSPLANT RECIPIENTS' named entity 'DAMAGE' named entity 'ELEVATED' named entity 'REPLICATION' named entity 'IMMUNOCOMPROMISED' named entity 'LINING' named entity 'SYSTEMIC' named entity 'ITS' named entity 'TO CONTROL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software